Skip to Main Navigation
Skip to Page Content

COVID-19 is an emerging, rapidly evolving situation.

Get the latest public health information from CDC and research information from NIH.

U.S. flag

An official website of the United States government

Dot gov

The .gov means it's official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Share This:
https://ntp.niehs.nih.gov/go/14830

Methyleugenol: Target Organs and Levels of Evidence for TR-491

Toxicology and Carcinogenesis Studies of Methyleugenol (CASRN 93-15-2) in F344/N Rats and B6C3F1 Mice (Gavage Studies)

Chemical (Study Title)
CASRN
Peer Review Date Route/Exposure Levels Study Laboratory
Methyleugenol
93-15-2
Gavage
0,10,30,100,300,1000 MG/KG PLUS SHAM GAVAGE GROUP
Southern Research Institute

Levels of Evidence: None



Chemical (Study Title)
CASRN
Peer Review Date Route/Exposure Levels Study Laboratory
Methyleugenol
93-15-2
10/30/1998 Gavage
R&M: 0, 37, 75, OR 150 MG/KG; 50/SEX/SPECIES/GROUP
Battelle Columbus Laboratory

Levels of Evidence

Male Rats: Clear Evidence
Type Organ/Tissue (Lesion)
Neoplastic Lesions
  • Liver: ADENOMA 5/50 12/50 23/50 38/50 32/50 OR CARCINOMA 2/50 3/50 14/50 25/50 36/50 COMBINED 7/50 14/50 28/50 43/50 45/50; HEPATOCHOLANGIOMA 0/50 0/50 0/50 1/50 6/50 OR HEPATOCHOLANGIOCARCINOMA 0/50 0/50 1/50 1/50 7/50 COMBINED 0/50 0/50 1/50 2/50 13/50
  • Glandular Stomach: BENIGN NEUROENDOCRINE TUMOR 1/50 0/50 0/50 3/50 2/50 OR MALIGNANT NEURENDOCRINE TUMOR 0/50 0/50 0/50 4/50 2/50 COMBINED 1/50 0/50 0/50 7/50 4/50
  • Kidney Tubular Cell: ADENOMA (STANDARD AND EXTENDED COMBINED) 4/50 6/50 17/50 13/50 20/50
  • Mesothelium (Abdominal Cavity/Tunica Vaginalis): MESOTHELIOMA 1/50 3/50 5/50 12/50 5/50
  • Mammary Gland: FIBROADENOMA 5/50 5/50 15/50 13/50 6/50
  • Skin: FIBROMA 1/50 9/50 8/50 5/50 4/50 OR FIBROMA OR FIBROSARCOMA 1/50 12/50 8/50 8/50 4/50
Non-Neoplastic Lesions
  • LIVER: EOSINOPHILIC FOCI, MIXED CELL FOCI; HEPATOCYTE HYPERTROPHY; OVAL CELL HYPERPLASIA; CYSTIC DEGENERATION
  • GLANDULAR STOMACH: NEUROENDOCRINE CELL HYPERPLASIA; ATROPHY
Female Rats: Clear Evidence
Type Organ/Tissue (Lesion)
Neoplastic Lesions
  • Liver: ADENOMA 1/50 8/50 11/49 33/49 43/50 OR CARCINOMA 0/50 0/50 4/49 8/49 22/50 COMBINED 1/50 8/50 14/49 34/49 43/50; HEPATOCHOLANGIOMA 0/50 0/50 0/49 0/49 8/50 OR HEPATOCHOLANGIOCARCINOMA 0/50 0/50 0/49 3/49 9/50 COMBINED 0/50 0/50 0/49 3/49 17/50
  • Glandular Stomach: BENIGN NEUROENDOCRINE TUMOR 0/50 0/50 13/50 9/50 5/50 OR MALIGNANT NEUROENDOCRINE TUMOR 0/50 1/50 12/50 26/50 36/50 COMBINED 0/50 1/50 25/50 34/50 41/50
May Have Been Related
  • Forestomach: SQUAMOUS CELL PAPILLOMA OR CARCINOMA 0/50 0/50 1/50 3/50
Non-Neoplastic Lesions
  • LIVER: EOSINOPHILIC FOCI, MIXED CELL FOCI; HEPATOCYTE HYPERTROPHY; OVAL CELL HYPERPLASIA, BILE DUCT HYPERPLASIA; CYSTIC DEGENERATION
  • GLANDULAR STOMACH: NEUROENDOCRINE CELL HYPERPLASIA; ATROPHY
Male Mice: Clear Evidence
Type Organ/Tissue (Lesion)
Neoplastic Lesions
  • Liver: ADENOMA 26/49 43/50 38/50 39/50 CARCINOMA 10/49 20/50 19/50 9/50 COMBINED 31/49 47/50 46/50 40/50; HEPATOBLASTOMA 0/49 0/50 1/50 3/50
  • Glandular Stomach: MALIGNANT NEUROENDOCRINE TUMOR 0/49 0/48 0/49 2/50
Non-Neoplastic Lesions
  • LIVER: EOSINOPHILIC FOCI; OVAL CELL HYPERPLASIA; HEPATOCYTE HYPERTROPHY
  • GLANDULAR STOMACH: ATROPHY; HYPERPLASIA; ECTASIA
Female Mice: Clear Evidence
Type Organ/Tissue (Lesion)
Neoplastic Lesions
  • Liver: ADENOMA 20/50 48/50 46/49 41/50 OR CARCINOMA 7/50 37/50 47/49 47/50 COMBINED 25/50 50/50 49/49 49/50; HEPATOBLASTOMA 0/50 6/50 11/49 15/50; HEPATOCHOLANGIOCARCINOMA 0/50 0/50 0/50 2/50
Non-Neoplastic Lesions
  • LIVER: OVAL CELL HYPERPLASIA; HEPATOCYTE HYPERTROPHY; HEPATOCYTE NECROSIS; HEMATOPOIETIC CELL PROLIFERATION; BILE DUCT HYPERPLASIA; HEMOSIDERIN PIGMENTATION
  • GRANDULAR STOMACH: ATROPHY; ECTASIA